FluMist, an experimental vaccine by biotech company MedImmune, would become the first vaccine to be delivered as a nasal spray, if it is approved by the FDA. FluMist's supporters say the vaccine would be a good alternative for people who dislike needles; children also may be able to be vaccinated against the flu with FluMist. Critics warn the vaccine has not been tested enough and a flu vaccine already exists.

Related Summaries